
Insulet’s Omnipod® 5 Pivotal Study Extension Data Shows Significant Improvements in Glycemic Control With One Year of Use
ACTON, Mass.–(BUSINESS WIRE)–Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, has presented positive pivotal trial extension phase results for the Omnipod® 5 Automated Insulin Delivery System (Omnipod 5). Omnipod 5, the world’s first tubeless, wearable system… Click here to view original post… […]